Abstract
Summary
The global artificial intelligence in life sciences market size reached US$ 1.48 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 6.58 Billion by 2027, exhibiting a growth rate (CAGR) of 26.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Artificial intelligence (AI) is a highly data-driven technology that is used in life sciences to collect, analyze, and manage data of patients. It is commonly employed for medical diagnosis, clinical trials, drug discovery, biotechnology, patient monitoring, precision, and personalized medicine. It is also utilized for producing personalized treatments, formulating drugs, diagnosing diseases, and introducing therapies and robotic surgeries. AI in life sciences helps reshape business models, enhance cognitive molecule research and workflow, and streamline biopharmaceutical manufacturing. It also saves valuable time, improves efficiency, reduces overall costs, enhances customer experience, and eliminates human error.
Artificial Intelligence In Life Sciences Market Trends:
At present, the rising prevalence of complex diseases, such as cancer, represents one of the key factors impelling the market growth. AI in life sciences is widely used to design effective drug combinations with specific molecular targets for patients. Additionally, the growing number of clinical trials across the globe is resulting in the surging production of colossal amounts of data available in the public domain. This, in turn, is creating lucrative opportunities for the market growth. Apart from this, the introduction of reliable and advanced cloud computing infrastructure that can easily manage, share, and store data and help improve organizational operations as per the requirements are providing a boost to the market. Moreover, the growing need to analyze and interpret large volumes of structured and unstructured clinical data is acting as another growth-inducing factor. Apart from this, extensive research and development (R&D) activities, rising utilization of robotics surgeries, and the implementation of various government initiatives to advance the medical infrastructure are anticipated to drive the market toward growth in the forecasted period.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial intelligence in life sciences market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on offering, deployment and application.
Breakup by Offering:
Software
Hardware
Services
Breakup by Deployment:
On-premises
Cloud-based
Breakup by Application:
Drug Discovery
Medical Diagnosis
Biotechnology
Clinical Trails
Precision and Personalized Medicine
Patient Monitoring
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AiCure LLC, Apixio Inc. (Centene Corporation), Atomwise Inc, Enlitic Inc., International Business Machines Corporation, Insilico Medicine Inc., Nuance Communications Inc., NuMedii Inc., Sensely Inc. and Sophia Genetics SA.
Key Questions Answered in This Report:
How has the global artificial intelligence in life sciences market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global artificial intelligence in life sciences market?
What are the key regional markets?
What is the breakup of the market based on the offering?
What is the breakup of the market based on the deployment?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global artificial intelligence in life sciences market and who are the key players?
What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Artificial Intelligence In Life Sciences Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Offering
6.1 Software
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Hardware
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Services
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Deployment
7.1 On-premises
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Cloud-based
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Application
8.1 Drug Discovery
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Medical Diagnosis
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Biotechnology
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Clinical Trails
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Precision and Personalized Medicine
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Patient Monitoring
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AiCure LLC
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
14.3.2 Apixio Inc. (Centene Corporation)
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
14.3.3 Atomwise Inc
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
14.3.4 Enlitic Inc
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
14.3.5 International Business Machines Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
14.3.6 Insilico Medicine Inc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
14.3.7 Nuance Communications Inc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
14.3.8 NuMedii Inc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
14.3.9 Sensely Inc
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
14.3.10 Sophia Genetics SA
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials